Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Phytochemical Engineering of Alternative Plant Proteins for Enhanced Nutrition and Digestibility.

Plant foods for human nutrition (Dordrecht, Netherlands)·2026
Same author

Deciphering the volatilome of Bacillus siamensis NKIT9: identification of potent antifungal volatile organic compounds against Rhizoctonia solani.

World journal of microbiology & biotechnology·2026
Same author

Patterns and associated factors of complementary and alternative therapy use for dysmenorrhea among undergraduate students in North India.

AJOG global reports·2026
Same author

Kirenol alleviates Th2-driven allergic asthma by modulating T-cell responses.

International immunopharmacology·2026
Same author

Pathobiology of Mycobacterium fortuitum and NTM biofilms: spotlight on emerging therapeutic horizons.

Advances in applied microbiology·2026
Same author

Antibiotic eluting collagen-based hydrogel improves wound healing in a biofilm challenged murine stented wound model.

Journal of applied biomaterials & functional materials·2026

相关实验视频

Updated: Sep 10, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K

针对不同型号的人类肺腺癌的一种新型基因酸基DC25酸酶抑制剂

Tsung-Ching Lai1, Iin Narwanti2, Bidyadhar Sethy3

  • 1Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; Pulmonary Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|August 21, 2025
PubMed
概括
此摘要是机器生成的。

新型化合物6有效抑制CDC25酸酶,对肺腺癌 (LUAD) 有强大的抗癌作用. 在临床前模型中,这种CDC25抑制剂通过抑制瘤生长和增强化疗效来显示治疗潜力.

关键词:
细胞亡酸酶抑制剂肺腺癌 肺腺癌来自患者的有机物形结构

更多相关视频

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.1K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

相关实验视频

Last Updated: Sep 10, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.7K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.1K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

科学领域:

  • 癌症学
  • 分子生物学
  • 药物发现

背景情况:

  • 细胞分裂周期25 (CDC25) 酸酶是关键的细胞周期调节剂,与瘤恶性有关.
  • CDC25的过度表达与预后不佳相关,使得CDC25成为癌症的重要治疗点.
  • 抑制CDC25抑制癌细胞的增殖并诱导细胞亡,这突显了其治疗意义.

研究的目的:

  • 开发具有潜在治疗应用的新型CDC25抑制剂.
  • 在肺癌模型中评估合成的CDC25抑制剂,特别是化合物6.
  • 在肺腺癌 (LUAD) 患者数据中调查CDC25表达的临床相关性.

主要方法:

  • 基于化合物NSC663284 (化合物1) 的CDC25抑制剂衍生物的合成和选.
  • 使用细胞活力测定,体外功能测定 (细胞毒性,细胞亡,殖民地形成,迁移,入侵) 和体内异种移植小鼠模型评估化合物的疗效.
  • 来自CPTAC和TCGA-LUAD数据集的临床数据分析,以将CDC25表达与预后和临床病理特征相关联.

主要成果:

  • 与化合物1相比,化合物6表现出强烈的CDC25酸酶抑制活性和更高的细胞毒性和亲亡作用.
  • 临床数据分析显示,高的CDC25A和CDC25C表达与LUAD的预后不佳和晚期瘤阶段有关.
  • 化合物6显著抑制了LUAD细胞的生长,迁移,侵袭和异种移植瘤的进展,并与化疗产生了协同作用.

结论:

  • 化合物6是对CDC25抑制的一种非常有前途的化合物.
  • 化合物6在体外和体内表现出显著的抗瘤活性,包括患者衍生器官.
  • 需要对化合物6进行进一步的研究,以确定其作为肺腺癌治疗剂的潜力.